- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
- Interventions
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Biological
- Lead sponsor
- AgonOx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2641–2664
of 9,820
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer, Head and Neck Cancer
- Interventions
- Urelumab, Cetuximab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Stanford, California • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Advanced Solid Tumor
- Interventions
- STX-003, KEYTRUDA®
- Biological
- Lead sponsor
- Strand Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pazopanib (GW786034)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Detroit, Michigan
- Conditions
- Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
- Interventions
- A-007
- Drug
- Lead sponsor
- DEKK-TEC, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- erlotinib, gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Palm Springs, California • Aurora, Colorado • Chapel Hill, North Carolina + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ABT-806
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
- Interventions
- AZD6244, MK-2206, Lapatinib, Erlotinib, Sunitinib, Molecular Profiling
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 647 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumors, Brain Tumors, Sarcoma, Pediatric Cancers, Neuroblastoma
- Interventions
- Recombinant human interleukin-15 (rhIL-15), NK Cell Infusion
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 29 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neoplasms, Breast
- Interventions
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg, pazopanib (GW786034) 800 mg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 19
- States / cities
- Jonesboro, Arkansas • Alhambra, California • Bakersfield, California + 16 more
- Conditions
- Locally Advanced Head and Neck Cancer
- Interventions
- Xtampza ER
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Liposarcoma, Leiomyosarcoma
- Interventions
- Yondelis, Dexamethasone
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Aurora, Colorado • Coeur d'Alene, Idaho + 17 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Cabozantinib, Docetaxel, Prednisone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, alisertib
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
- Interventions
- NBTXR3, SABR, Nivolumab, Pembrolizumab
- Drug · Radiation
- Lead sponsor
- Nanobiotix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 13
- States / cities
- San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- oral belinostat
- Drug
- Lead sponsor
- Valerio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York • Houston, Texas
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- doxorubicin hydrochloride
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 2
- States / cities
- New York, New York • Columbus, Ohio
- Conditions
- BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
- Interventions
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Vemurafenib
- Biological · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
- Conditions
- Cancer, Neoplasm
- Interventions
- SAR444881, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Duarte, California • Aurora, Colorado + 6 more
- Conditions
- Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
- Interventions
- Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
- Drug
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
- Conditions
- Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma, Locally Advanced Head and Neck Cancer
- Interventions
- Toripalimab, Carboplatin, Docetaxel, Radiation Therapy, Cisplatin
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage III Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
- Interventions
- oblimersen sodium, cisplatin, fluorouracil
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
- Interventions
- Nivolumab, Nivolumab + Relatlimab, Ipilimumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida